Koivunen et al. suggested that PHD inhibition showed a therapeutic role in anemia, cardiac ischemia, obesity and metabolic dysfunction, and atherosclerosis by stabilizing HIF to promote glucose intake and glycolysis over oxidative metabolism35. Here, PDC is linked to obesity disorder.